Last reviewed · How we verify
thiomersal
thiomersal is a drug. It is currently in unknown development.
At a glance
| Generic name | thiomersal |
|---|---|
| Target | 5-hydroxytryptamine receptor 6, Adenosine receptor A3, Mitogen-activated protein kinase 3 |
| Therapeutic area | Other |
| Phase | unknown |
Approved indications
Common side effects
Key clinical trials
- A Dose-Finding Study to Assess the Safety, Tolerability, and Immunogenicity of Inactivated Streptococcus Pneumoniae Whole Cell Vaccine Formulated With Alum (PATH-wSP) in Healthy Kenyan Young Adults an (Phase 1)
- A Randomized, Double-Blind Trial on the Safety and Immunogenicity of Seasonal 2010-2011 Inactivated Trivalent Influenza Vaccine in Pregnant Women (Phase 2)
- A Randomized, Double-Blind Trial Evaluating the Safety and Immunogenicity of an Influenza Vaccine With Reduced Preservative (FluLaval™ TR) and a Standard Influenza Vaccine (Fluarix®) in Subjects Betwe (Phase 3)
- A Randomized, Observer Blinded, Controlled Trial to Evaluate the Safety and Immunogenicity of a New Formulation of Euvichol® (Killed Bivalent Whole Cell Oral Cholera Vaccine Manufactured by EuBiologic (Phase 3)
- A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2013/2014 Formulation of the Enzira® Vaccine in Two Groups of Healthy Volunteers: 'Adults' (Aged 18 to 59 Y (Phase 4)
- A Phase III, Single-Blind, Multi-Center, Extension Study to Evaluate Safety and Tolerability of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eg (Phase 3)
- A Randomized, Open Label, Single Center, Dose- and Regimen-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and Non-Adjuvanted Egg-Derived, (Phase 3)
- Open Label Parallel Randomized Clinical Trial to Evaluate the Immunogenicity of Three Regimens of the Trivalent Influenza Vaccine (Inactivated and Fragmented) in Kidney Transplant Recipients (Phase 4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- thiomersal CI brief — competitive landscape report
- thiomersal updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about thiomersal
What is thiomersal?
thiomersal is a pharmaceutical drug.
What development phase is thiomersal in?
thiomersal is in unknown.
What does thiomersal target?
thiomersal targets 5-hydroxytryptamine receptor 6, Adenosine receptor A3, Mitogen-activated protein kinase 3.
Related
- Target: All drugs targeting 5-hydroxytryptamine receptor 6, Adenosine receptor A3, Mitogen-activated protein kinase 3
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing